

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Linzagolix for treating pain caused by endometriosis ID6357

Provisional Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
<u>Company</u>	<u>General</u>
Theramex (linzagolix)	 All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Action on Pain	Board of Community Health Councils in
British Fibroid Trust	Wales
Endometriosis UK	British National Formulary
Fertility Network UK	Care Quality Commission
Fibroid Network	Department of Health, Social Services
Go Girls	and Public Safety for Northern Ireland
Pain Concern	Healthcare Improvement Scotland
Pain UK	Medicines and Healthcare products
Peaches Womb Cancer Trust	Regulatory Agency
Pelvic Pain Support Network	National Association of Primary Care
South Asian Health Foundation	National Pharmacy Association
Specialised Healthcare Alliance	NHS Confederation
Wellbeing of Women	Scottish Medicines Consortium
Womb Cancer Support UK	Welsh Government
Women's Health Concern	 Welsh Health Specialised Services Committee
Healthcare professional groups	
British and Irish Association of Robotic	Possible comparator companies
Gynaecological Surgeons	Adalvo (dienogest)
British Fertility Society	AstraZeneca (goserelin acetate)
British Pain Society	Bayer (combined hormonal
British Society for Gynaecological	contraception, levonorgestrel,
Endoscopy	norethisterone)
Primary Care Women's Health Forum	Besins Healthcare (progesterone,
Royal College of General Practitioners	dienogest)
Royal College of Nursing	Crescent Pharma (dienogest)
Royal College of Obstetricians and	Esteve Pharmaceuticals (gonadorelin)
Gynaecologists	Ferring Pharmaceuticals (triptorelin)
Royal College of Pathologists	Gedeon Richter (relugolix CT,
Royal College of Physicians	dienogest)
Royal Pharmaceutical Society	Ipsen Ltd (triptorelin)
Royal Society of Medicine	Lupin Healthcare (combined hormonal
UK Clinical Pharmacy Association	contraceptive)

Provisional stakeholder list for the evaluation of linzagolix for treating pain caused by endometriosis ID6357



Consultees	Commentators (no right to submit or appeal)
Others Department of Health and Social Care NHS England	 Morningside Healthcare (combined hormonal contraception) Mylan (combined hormonal contraception) NAARI B.V. (dienogest) Neon Healthcare (buserelin) Organon Pharma (combined hormonal contraception) Pfizer (combined hormonal contraception, nafarelin) Stragen UK (dienogest) Takeda (leuprorelin acetate)
	 Relevant research groups Campbell Collaboration Social Welfare Group Cochrane Menstrual Disorders and Subfertility Group Cochrane UK Genomics England MRC Clinical Trials Unit National Institute for Health Research Pain Relief Foundation Associated Public Health groups
	Public Health WalesUK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of linzagolix for treating pain caused by endometriosis ID6357

Issue date: March 2024



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.